Takeda chief finds right growth plan

Japanese pharmaceutical company expects double-digit surge in 3 key market segments

Takeda Pharmaceutical Co Ltd, considered Asia's largest drugs company by sales, expects China to lead the industry's growth across the emerging markets.

Officials at the Japanese company predict that the China market will enjoy 25 percent compound annual growth until 2017, much higher than other main emerging markets, which they say will have an average of 13 percent annual growth.